TB

This monograph provides information for use by tribal, state, and local public health practitioners and their legal counsel to help improve their understanding and use of relevant laws to respond to challenges concerning TB control. Part I of the monograph contains an introduction and table listing resources on communicable disease and TB control methods in selected US jurisdictions. Part II presents a brief overview of some of the essential components of TB control, including a discussion of the international and national threats of the disease and modern public health interventions.

This report is the annual compilation of data from World Health Organization’s (WHO) 193 member states. It provides a summary of the current status of national health and health systems, including mortality and burden of disease, causes of death, reported infectious diseases, health service coverage, risk factors, health systems resources, health expenditures, inequities, and demographic and socioeconomic statistics.

This report describes the investigation by the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), which initially identified five confirmed cases of multidrug-resistant tuberculosis (MDR TB) in two distinct clusters, characterized by two distinct geographic locations, genotypes, and drug-susceptibility patterns in the Federated States of Micronesia. Extensive transmission had occurred among household contacts; 16 (8%) of the 205 contacts identified had confirmed or suspected MDR TB disease, and 124 (60%) had latent TB infection.

This report describes the investigation of a genotype cluster of eight tuberculosis cases in US born patients in the Detroit metropolitan area. The investigation was done by the Detroit Department of Health and Wellness Promotion, the Michigan Department of Community Health, and the Centers for Disease Control and Prevention. The first case was reported in a patient with drug-susceptible TB, who subsequently developed multidrug-resistant TB (MDR TB). Seven additional cases were reported in patients with TB genotypes matching that of the index patient.

This report presents the Centers for Disease Control and Prevention's (CDC) updated recommendations on the use of nucleic acid amplification tests (NAA) for TB diagnosis. These revised guidelines were developed on the basis of a report by a panel of clinicians, laboratorians, and TB control officials. The panel was convened by CDC and the Association of Public Health Laboratories (APHL) and in consultation with the Advisory Council for the Elimination of TB (ACET).

This report on the uses of nucleic acid amplification (NAA) tests for diagnosis of TB is based on contributions of an expert panel of consultants convened by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL).

This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to provide access to rapid drug-susceptibility testing to all TB control programs in the United States. The panel recommended that CDC establish regional laboratories to provide molecular drug-resistance testing services to state and local TB programs.

This report provides World Health Organization (WHO) member states with guidance on preventing TB transmission in healthcare facilities, congregate settings, and households. It focuses on what to do and how to prioritize TB infection control at national levels and includes recommendations for national managerial activities. The report updates or presents new or increased emphasis on the particular administrative and environmental controls to be implemented and on personal protective equipment. It includes a special focus on building design and use of space.

This report describes a study that determined whether differences in national trends in tuberculosis (TB) incidence are attributable to the variable success of control programs or to biological, social, and economic factors. Trends in case notifications were used as a measure of trends in incidence in 135 countries from 1997-2006, and regression analysis was used to explore the associations between these trends and 32 measures covering aspects of development, the economy, the population, behavioral and biological risk factors, health services, and TB control.

This video illustrates the interactions between TB and HIV, including their impact on the immune system, TB testing, and TB treatment.